|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Information provided by: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| ClinicalTrials.gov Identifier: | NCT00093990 |
Purpose
This study tests the effectiveness of tipifarnib in older patients with acute myeloid leukemia.
In this study, half the patients will receive tipifarnib and the other half of the patients will receive the standard treatment of the hospital.
| Condition | Intervention | Phase |
|
Myeloid Leukemia Acute Disease |
Procedure: Bone marrow aspirate Drug: Tipifarnib |
Phase III |
| ChemIDplus related topics: | Hydroxyurea Tipifarnib |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or Older (Farnesyl Transferase Inhibition Global Human Trials AML 301 [F.I.G.H.T. AML 301]) |
Eligibility
| Ages Eligible for Study: | 70 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Serum biochemical values as follows:
Contacts and Locations![]() |
Show 134 Study Locations |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Study Director: | Johnson & Johnson Pharmaceutical Research and Development L.L.C. Clinical Trial | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
More Information
| Study ID Numbers: | R115777-AML-301 |
| First Received: | October 7, 2004 |
| Last Updated: | September 20, 2007 |
| ClinicalTrials.gov Identifier: | NCT00093990 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|